Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat PK and Safety in Cancer Patients with Renal or Hepatic Impairment
NCT03814005Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pevonedistat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) and 1 more (4 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Jul 2019; status: completed.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03814005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814005.